Record mula sa primary source
Decision-gradeTopline na resulta
Aldeyra nag-uulat ng positibong Phase 2 topline para sa ADX-629 sa alcohol-associated hepatitis
ADX-629 ay nakamit ang pangunahing layunin nito, na nagpapakita ng mga istatistikal na makabuluhang pagpapabuti sa MELD score, triglycerides, at CRP kumpara sa baseline sa 4-pasyenteng Phase 2 trial. Aldeyra ay itinitigil ang karagdagang pag-unlad ng ADX-629 at inililipat ang mga mapagkukunan sa susunod na henerasyong RASP modulators ADX-248 at ADX-246, na nagpapahaba ng cash runway hanggang sa ikalawang kalahati ng 2027.
Mahahalagang fact
- Na-file
- Okt 28, 2025, 11:00 AM
- Kaganapan
- Topline na resulta
- Direksyon
- Positibo
- Kumpanya
ALDXAldeyra- Asset
- ADX-629
- Pinagmulan
- SEC 8-K
- Kumpiyansa
- May source
- Mga pasyente
- 4
- Taning ng pondo
- H2 2027
- P-value ng antas ng CRP
- <0.0001
- P-value ng iskor na MELD
- 0.001
- P-value ng antas ng trigliserido
- <0.0001
Sipi mula sa source
EX-99.1 2 aldx-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 News Release Aldeyra Therapeutics Announces Positive Results from Phase 2 Clinical Trial in Alcohol-Associated Hepatitis, Focuses RASP Product Candidate Pipeline on Next-Generation Molecules • Relative to Baseline, Signal-Finding Molecule ADX‑629 Demonstrated Statistically Significant Improvement in Liver Function in Patients with Alcohol-Associated Hepatitis • RASP Modulator Product Candidate Pipeline Focused on ADX‑248 and ADX‑246 for Dermatologic, Metabolic, and Retinal Immune-Mediated Diseases • Cash Runway Extended into the Second Half of 2027 Lexington, Mass. October 28, 2025 – Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed t